Kairos Pharma Receives Food and drug administration Acceptance of Investigational New Drug (IND) Software for Its Phase 1 Medical Trial of KROS 201 for the Treatment of Glioblastoma Announces New Patent for KROS 401

Section 1 scientific trial of KROS 201 to get started in 2022 at Cedars Sinai Clinical Heart

New patent covers the approach of treating fibrosis and selected kinds of most cancers, the composition of issue, and administering a therapy using KROS-401

LOS ANGELES, March 14, 2022 /PRNewswire/ — Kairos Pharma, Ltd. (“Kairos”), a privately held clinical stage biotechnology organization concentrated on drug resistance and immunotherapy for cancer, currently introduced that its activated T cell therapy, KROS 201, has acquired Fda acceptance to proceed with a Period 1 scientific demo in sufferers with recurrent glioblastoma, a form of brain most cancers. The section I trial is sponsored by Kairos Pharma and will be carried out at Cedars Sinai Health-related Centre in Los Angeles.

Kairos Pharma

Kairos CEO John Yu, M.D. commented, “This IND acceptance is the second considerable clinical milestone inside of the earlier month as Kairos accelerates towards its medical aims for 2022. This initially-in-man Period 1 clinical trial will activate T cells versus the most cancers stem cells at the root of glioblastoma.”

Kairos Main Scientific Officer Neil Bhowmick, Ph.D. added, “This achievement pushes the envelope of immune therapies intended to goal T cells from devastating cancers.”

KROS 201 activated T cells (ATCs) are killer T cells that are formulated in a mobile lifestyle by activating a a patient’s white blood cells with cytokines or T mobile activating indicators and by priming dendritic cells loaded with glioblastoma most cancers stem cell distinct antigens. The powerful activated T cells are infused intravenously into sufferers with recurrent glioblastoma. These cells have been demonstrated to kill cancer stem cells, the root induce of cancer.

In addition to the future Phase 1 demo of activated T mobile remedy for KROS 201, a Period 2 trial of ENV105 with apalutamide was not too long ago granted an IND by the Fda in February. A Period 1 trial of ENV105 with Tagrisso (AstraZeneca) for lung most cancers is planned to start in 2022.

Alongside with this development of its clinical milestones, Kairos Pharma declared a discover of allowance of the United States Patent and Trademark Business of their patent Compositions and Techniques for Dealing with Fibrosis. This patent addresses the technique of treating fibrosis and certain sorts of cancer, the composition of matter, and administering a treatment applying KROS-401, a cyclic peptide inhibitor of the IL-4 and IL-13 cytokine receptor sophisticated. This therapeutic has been revealed to address both of those fibrosis and cancer by reversing the M1 to M2 immunosuppressive macrophage changeover in both of those cancers and fibrosis.

Dr. John Yu, CEO of Kairos Pharma mentioned, “This milestone further supports the previously substantial and diversified mental home portfolio of Kairos and enables the unfettered medical advancement of this novel and transformative therapeutic.”

Kairos VP of Investigation and Enhancement Dr. Ramachandran Murali, inventor of the KROS 401 molecule, commented, “KROS-401, in addition to fibrosis and cancer, opens a new avenue in therapeutic growth for neurological disorders these kinds of as Alzheimer’s ailment.”

About Kairos Pharma

Kairos Pharma is a scientific-stage biopharmaceutical corporation focused on creating a diversified pipeline of reducing-edge therapeutics for cancer sufferers that reverse the inhibitory results of cancer on the immune method. The Company’s exceptional portfolio of seven drug candidates is anchored by a new course of novel medicine that reverse drug resistance and immune resistance to most cancers. The Company has manufactured unparalleled strides as a result of its transformative engineering, sturdy IP, and world-course crew operating to make a significant affect on the most pervasive troubles in cancer treatment. kairospharma.com.

Ahead-Searching Statements

This push launch might have “forward-searching statements” with regards to Kairos Pharma’s existing anticipations and projections about foreseeable future situations. “Forward-on the lookout statements” (statements as to issues other than historical information) as outlined in the Non-public Securities Litigation Reform Act of 1995 can be identified by terminology these kinds of as: “will,” “prospective”, “could,” “can,” “believe,” “intends,” “keep on,” “plans,” “expects,” “projects,” “estimates,” “anticipates,” “believes,” or equivalent language. These statements are primarily based on present beliefs and expectations and are topic to quite a few pitfalls and uncertainties which are difficult to foresee and forecast. No ahead-seeking statements can be assured, and actual success might vary materially from this kind of statements. The info in this presentation is provided only as of the day of this presentation and Kairos Pharma, Ltd. will take no obligation to update any forward-wanting statements contained in this presentation primarily based on new information of long term gatherings and/or effects. These forward-looking statements are topic to known and unfamiliar pitfalls, uncertainties, assumptions and other aspects that could trigger the Company’s true outcomes, efficiency or achievements to be materially diverse than any long run benefits, functionality or achievements expressed or implied by the ahead-looking statements. Genuine final results may well vary materially from those people indicated by these ahead- on the lookout statements as a consequence of different important things, together with the Company’s skill to learn and acquire its novel product or service candidates and efficiently demonstrate the efficacy and security of its products candidates the pre-scientific and clinical effects for its merchandise candidates, which might not support even further improvement of item candidates steps of the Company’s collaborators regarding ongoing merchandise growth and product commercialization steps of regulatory authorities, which may perhaps have an impact on the initiation, timing and progress of clinical trials or the skill of the Company to get hold of advertising and marketing authorization for its merchandise candidates the Firm’s skill to get, keep and safeguard its intellectual house the Firm’s capacity to implement its patents towards infringers and defend its patent portfolio from difficulties from 3rd functions competitiveness from some others using engineering related to the Company’s and other folks acquiring products for very similar makes use of the Firm’s potential to deal with operating fees the Firm’s means to receive added funding to help its enterprise activities and set up and manage its current and long run collaborations and new enterprise initiatives the Firm’s dependence on collaborators and other 3rd parties for enhancement, manufacture, internet marketing, sales and distribution of solutions the consequence of litigation and unpredicted expenses. Any forward-hunting statements stand for the Company’s sights only as of the date of this push launch and should really not be relied upon as symbolizing its sights as of any subsequent day. The Company explicitly disclaims any obligation to update any forward-searching statements.

Cision

Cision

Perspective unique content material to download multimedia:https://www.prnewswire.com/news-releases/kairos-pharma-receives-food and drug administration-acceptance-of-investigational-new-drug-ind-software-for-its-section-1-scientific-trial-of-kros-201-for-the-remedy-of-glioblastoma-announces-new-patent-for-kros-401-301502125.html

Source Kairos Pharma, Ltd.